Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease-Reference-Cited by-同舟云学术

Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease

Published:2016-01 Issue:1 Volume:2 Page:1-12
ISSN:2352-8737
Container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions
language:en
Short-container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions

Author:

Satlin Andrew¹,Wang Jinping¹,Logovinsky Veronika¹,Berry Scott²,Swanson Chad¹,Dhadda Shobha¹,Berry Donald A.²

Affiliation:

1. Neuroscience & General Medicine, Eisai Inc.; Woodcliff Lake NJ USA

2. Berry Consultants, LLC; Austin TX USA

Funder

Eisai, Inc., Woodcliff Lake, NJ, United States

Publisher

Wiley

Subject

Psychiatry and Mental health,Neurology (clinical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1016/j.trci.2016.01.001/fullpdf

Reference55 articles.

1. Alzheimer's disease drug-development pipeline: few candidates, frequent failures;Cummings;Alzheimers Res Ther,2015

2. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results;Sparks;Arch Neurol,2005

3. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe;Feldman;Neurology,2010

4. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease;Salloway;Neurology,2009

5. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease;Salloway;N Engl J Med,2014

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targets, trials and tribulations in Alzheimer therapeutics;European Journal of Pharmacology;2024-01

2. Optimizing the doses of cancer drugs after usual dose finding;Clinical Trials;2023-12-27

3. From Recognition to Remedy: The Significance of Biomarkers in Neurodegenerative Disease Pathology;International Journal of Molecular Sciences;2023-11-09

4. Landscape of Phase II Trials in Alzheimer’s Disease;Journal of Alzheimer's Disease;2023-11-07

5. Decision making in clinical trials: Interim analyses, innovative design, and biomarkers;Alzheimer's & Dementia: Translational Research & Clinical Interventions;2023-10